Alps Group Inc reported a 44% year-over-year revenue increase to $4.86 million for fiscal 2026, fueled by strong expansion in cellular therapy sales and medical testing, laboratory, and aesthetic services in Southeast Asia. The company launched a patient-derived organoid program advancing personalized cancer care and achieved Whole Genome Sequencing accreditation, signaling clinical capability enhancement. Despite improving gross profit, the growing contribution of lower-margin aesthetic services has compressed overall gross margin to 32.1%, with net losses narrowing but continuing amid elevated operating costs and investment in pipeline development. Alps balances its commercial operations with early-stage biotechnology research, while liquidity constraints and material weaknesses in financial controls represent ongoing risks.